Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.45 |
| ▸ | TTPA | P49638 | 3/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633931 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL29670772 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL6362676 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL22899966 | 0.90 | PTGS1 (0.70) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15851247 | 0.90 | PTGS1 (0.56) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL31326006 | 0.87 | PTGS1 (0.65) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL30951067 | 0.86 | PTGS1 (0.68) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2393197 | 0.86 | PTGS1 (0.68) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL21344343 | 0.86 | PTGS1 (0.52) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL7895023 | 0.86 | PTGS1 (0.91) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
| US-9220787-B2 | Vitamin E conjugates, and their uses as antioxidants and prodrug delivery vehicles | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220787-B2 | Vitamin E conjugates, and their uses as antioxidants and prodrug delivery vehicles | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220787-B2 | Vitamin E conjugates, and their uses as antioxidants and prodrug delivery vehicles | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2351729-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ORGANIC CARBOXYLIC ACID | MITSUBISHI GAS CHEMICAL CO (JP) | 2014-01-22 | — | — | EP | disclosed |
| EP-2418948-B1 | ANTIADHESION AGENTS | UNIV OHIO STATE RES FOUND (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130210702-A1 | Vitamin E Conjugates, and Their Uses as Antioxidants and Prodrug Delivery Vehicles | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2013-08-15 | — | — | US | disclosed |
| US-20130210702-A1 | Vitamin E Conjugates, and Their Uses as Antioxidants and Prodrug Delivery Vehicles | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2013-08-15 | — | — | US | disclosed |
| US-20100063305-A1 | METHOD OF PRODUCING S-(-)-6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMANE-2-CARBOXYLIC ACID AND PRODUCT OBTAINED BY THE METHOD | Mitsubishi Gas Chemcial (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2088144-A1 | METHOD OF PRODUCING S-(-)-6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMANE-2-CARBOXYLIC ACID AND PRODUCT OBTAINED BY THE METHOD | Mitsubishi Gas Chemical Company, Inc. (JP) | 2009-08-12 | — | — | EP | disclosed |
| US-20080161349-A1 | TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMAN AND SIDE CHAIN DERIVATIVES AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080009545-A1 | Anticancer agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-4788214-A | ANTIALLERGENS | HOFFMAN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4785017-A | ANTIALLERGENS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-15 | — | — | US | disclosed |
| EP-0003221-B1 | PROCESS FOR THE MANUFACTURE OF 3,4-DIHYDRO-BENZOPYRAN DERIVATIVES AND STARTING MATERIALS IN THIS PROCESS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-04-21 | — | — | EP | disclosed |
| US-4205001-A | Inversion process | HOFFMANN-LA ROCHE INC. (US) | 1980-05-27 | — | — | US | disclosed |
| EP-0003221-A2 | Process for the manufacture of 3,4-dihydro-benzopyran derivatives and starting materials in this process | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-08-08 | — | — | EP | disclosed |
| US-4150050-A | 3,6-Dioxo-1,4-cyclohexadien-1-yl-butandate esters | HOFFMANN-LA ROCHE INC. (US) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063305-A1 | METHOD OF PRODUCING S-(-)-6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMANE-2-CARBOXYLIC ACID AND PRODUCT OBTAINED BY THE METHOD | HAO2, CYP7A1, CYP8B1 | PTGS1 780/4885PTGS2 653/4885CYP1A2 26/4885 |
| US-20130210702-A1 | Vitamin E Conjugates, and Their Uses as Antioxidants and Prodrug Delivery Vehicles | TTPA, VSIR, FOLR1 | PTGS1 1930/4885PTGS2 2571/4885CYP1A2 2410/4885 |
| US-20080009545-A1 | Anticancer agents | SUCNR1, CPS1, HIF1AN | PTGS1 760/4885PTGS2 1541/4885CYP1A2 512/4885 |
| US-20080161349-A1 | TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMAN AND SIDE CHAIN DERIVATIVES AND USES THEREOF | TST, TXNRD3, TXNRD1 | PTGS1 367/4885PTGS2 615/4885CYP1A2 1344/4885 |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | PTGS1 959/4885PTGS2 528/4885CYP1A2 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.